Ocular Therapeutix Inc (OCUL)

$3.18

-0.04

(-1.24%)▲

Market is closed - opens 7 PM, 28 Sep 2023

Insights on Ocular Therapeutix Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 13.37M → 15.02M (in $), with an average increase of 11.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -30.31M → -20.68M (in $), with an average increase of 46.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 91.4% return, outperforming this stock by 116.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 165.8% return, outperforming this stock by 225.0%

Performance

  • $3.15
    $3.29
    $3.18
    downward going graph

    0.94%

    Downside

    Day's Volatility :4.26%

    Upside

    3.34%

    downward going graph
  • $2.57
    $7.96
    $3.18
    downward going graph

    19.18%

    Downside

    52 Weeks Volatility :67.71%

    Upside

    60.05%

    downward going graph

Returns

PeriodOcular Therapeutix IncSector (Health Care)Index (Russel 2000)
3 Months
-34.29%
-0.9%
0.0%
6 Months
-37.35%
1.5%
1.0%
1 Year
-25.29%
7.1%
6.4%
3 Years
-59.24%
25.9%
19.9%

Highlights

Market Capitalization
253.2M
Book Value
$0.04
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.14
PEG Ratio
0.0
Wall Street Target Price
13.13
Profit Margin
-166.17%
Operating Margin TTM
-153.89%
Return On Assets TTM
-35.53%
Return On Equity TTM
-263.41%
Revenue TTM
54.6M
Revenue Per Share TTM
0.71
Quarterly Revenue Growth YOY
23.799999999999997%
Gross Profit TTM
-6.5M
EBITDA
-81.9M
Diluted Eps TTM
-1.14
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.16
EPS Estimate Next Year
-0.93
EPS Estimate Current Quarter
-0.3
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Ocular Therapeutix Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 312.89%

Current $3.18
Target $13.13

Company Financials

FY17Y/Y Change
Revenue
1.9M
↑ 1.91%
Net Income
-63.4M
↑ 41.79%
Net Profit Margin
-3.3K%
↓ 927.2%
FY18Y/Y Change
Revenue
2.0M
↑ 3.48%
Net Income
-60.0M
↓ 5.38%
Net Profit Margin
-3.0K%
↑ 282.23%
FY19Y/Y Change
Revenue
4.2M
↑ 112.41%
Net Income
-86.4M
↑ 44.01%
Net Profit Margin
-2.0K%
↑ 970.63%
FY20Y/Y Change
Revenue
17.4M
↑ 311.71%
Net Income
-155.6M
↑ 80.19%
Net Profit Margin
-894.31%
↑ 1149.03%
FY21Y/Y Change
Revenue
43.5M
↑ 150.08%
Net Income
-6.6M
↓ 95.79%
Net Profit Margin
-15.06%
↑ 879.25%
FY22Y/Y Change
Revenue
51.5M
↑ 18.32%
Net Income
-71.0M
↑ 984.05%
Net Profit Margin
-137.95%
↓ 122.89%
Q1 FY22Q/Q Change
Revenue
13.2M
↑ 7.14%
Net Income
-12.5M
↑ 225.77%
Net Profit Margin
-95.11%
↓ 63.83%
Q2 FY22Q/Q Change
Revenue
12.3M
↓ 6.98%
Net Income
-18.8M
↑ 49.63%
Net Profit Margin
-152.99%
↓ 57.88%
Q3 FY22Q/Q Change
Revenue
12.0M
↓ 2.45%
Net Income
-24.2M
↑ 28.89%
Net Profit Margin
-202.16%
↓ 49.17%
Q4 FY22Q/Q Change
Revenue
14.1M
↑ 17.64%
Net Income
-15.5M
↓ 35.74%
Net Profit Margin
-110.41%
↑ 91.75%
Q1 FY23Q/Q Change
Revenue
13.4M
↓ 4.99%
Net Income
-30.3M
↑ 95.07%
Net Profit Margin
-226.69%
↓ 116.28%
Q2 FY23Q/Q Change
Revenue
15.0M
↑ 12.37%
Net Income
-20.7M
↓ 31.78%
Net Profit Margin
-137.61%
↑ 89.08%
FY17Y/Y Change
Total Assets
55.4M
↓ 26.03%
Total Liabilities
29.3M
↑ 27.7%
FY18Y/Y Change
Total Assets
73.0M
↑ 31.77%
Total Liabilities
37.2M
↑ 26.92%
FY19Y/Y Change
Total Assets
78.7M
↑ 7.8%
Total Liabilities
82.4M
↑ 121.62%
FY20Y/Y Change
Total Assets
261.9M
↑ 232.57%
Total Liabilities
185.8M
↑ 125.53%
FY21Y/Y Change
Total Assets
204.9M
↓ 21.76%
Total Liabilities
116.9M
↓ 37.08%
FY22Y/Y Change
Total Assets
149.3M
↓ 27.14%
Total Liabilities
113.9M
↓ 2.55%
Q1 FY22Q/Q Change
Total Assets
187.6M
↓ 8.43%
Total Liabilities
107.8M
↓ 7.75%
Q2 FY22Q/Q Change
Total Assets
173.1M
↓ 7.76%
Total Liabilities
107.3M
↓ 0.52%
Q3 FY22Q/Q Change
Total Assets
158.6M
↓ 8.37%
Total Liabilities
112.4M
↑ 4.74%
Q4 FY22Q/Q Change
Total Assets
149.3M
↓ 5.86%
Total Liabilities
113.9M
↑ 1.39%
Q1 FY23Q/Q Change
Total Assets
128.6M
↓ 13.88%
Total Liabilities
118.9M
↑ 4.35%
Q2 FY23Q/Q Change
Total Assets
122.6M
↓ 4.68%
Total Liabilities
119.5M
↑ 0.51%
FY17Y/Y Change
Operating Cash Flow
-50.5M
↑ 48.45%
Investing Cash Flow
27.1M
↓ 23.9%
Financing Cash Flow
32.0M
↑ 5371.45%
FY18Y/Y Change
Operating Cash Flow
-49.2M
↓ 2.47%
Investing Cash Flow
-1.9M
↓ 106.98%
Financing Cash Flow
68.6M
↑ 114.45%
FY19Y/Y Change
Operating Cash Flow
-77.6M
↑ 57.59%
Investing Cash Flow
-2.2M
↑ 18.48%
Financing Cash Flow
75.3M
↑ 9.76%
FY20Y/Y Change
Operating Cash Flow
-53.6M
↓ 30.97%
Investing Cash Flow
-841.0K
↓ 62.42%
Financing Cash Flow
228.0M
↑ 202.64%
FY21Y/Y Change
Operating Cash Flow
-65.6M
↑ 22.4%
Investing Cash Flow
-1.2M
↑ 41.97%
Financing Cash Flow
2.9M
↓ 98.75%
FY22Y/Y Change
Operating Cash Flow
-59.6M
↓ 9.07%
Investing Cash Flow
-3.7M
↑ 211.14%
Financing Cash Flow
1.5M
↓ 49.0%
Q1 FY22Q/Q Change
Operating Cash Flow
-18.6M
↑ 22.75%
Investing Cash Flow
-276.0K
↓ 56.26%
Financing Cash Flow
129.0K
↓ 80.66%
Q2 FY22Q/Q Change
Operating Cash Flow
-10.9M
↓ 41.53%
Investing Cash Flow
-495.0K
↑ 79.35%
Financing Cash Flow
493.0K
↑ 282.17%
Q3 FY22Q/Q Change
Operating Cash Flow
-13.2M
↑ 21.08%
Investing Cash Flow
-794.0K
↑ 60.4%
Financing Cash Flow
374.0K
↓ 24.14%
Q4 FY22Q/Q Change
Operating Cash Flow
-17.0M
↑ 28.77%
Investing Cash Flow
-2.2M
↑ 170.78%
Financing Cash Flow
458.0K
↑ 22.46%
Q1 FY23Q/Q Change
Operating Cash Flow
-20.0M
↑ 17.78%
Investing Cash Flow
-3.4M
↑ 57.16%
Financing Cash Flow
78.0K
↓ 82.97%
Q2 FY23Q/Q Change
Operating Cash Flow
-20.1M
↑ 0.51%
Investing Cash Flow
-2.0M
↓ 41.11%
Financing Cash Flow
9.6M
↑ 12265.38%

Technicals Summary

Sell

Neutral

Buy

Ocular Therapeutix Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ocular Therapeutix Inc
Ocular Therapeutix Inc
-15.04%
-37.35%
-25.29%
-59.24%
-53.8%
Moderna, Inc.
Moderna, Inc.
-13.8%
-33.86%
-19.73%
39.08%
427.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.18%
1.46%
19.77%
45.55%
105.03%
Novo Nordisk A/s
Novo Nordisk A/s
-2.09%
18.67%
91.43%
165.4%
285.43%
Seagen, Inc.
Seagen, Inc.
4.8%
8.3%
59.7%
13.46%
176.24%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.03%
14.01%
23.51%
31.36%
85.35%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ocular Therapeutix Inc
Ocular Therapeutix Inc
NA
NA
0.0
-1.16
-2.63
-0.36
0.0
0.04
Moderna, Inc.
Moderna, Inc.
35.31
35.31
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.73
21.73
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
42.99
42.99
2.03
1.65
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.12
27.12
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ocular Therapeutix Inc
Ocular Therapeutix Inc
Buy
$253.2M
-53.8%
NA
-166.17%
Moderna, Inc.
Moderna, Inc.
Buy
$37.4B
427.53%
35.31
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.4B
105.03%
21.73
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$407.6B
285.43%
42.99
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$40.6B
176.24%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.8B
85.35%
27.12
35.4%

Institutional Holdings

  • SUMMER ROAD LLC

    7.71%

  • Opaleye Management Inc

    7.28%

  • BlackRock Inc

    6.63%

  • Vanguard Group Inc

    5.11%

  • Millennium Management LLC

    3.02%

  • Deltec Asset Management LLC

    2.49%

Corporate Announcements

  • Ocular Therapeutix Inc Earnings

    Ocular Therapeutix Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib

Organization
Ocular Therapeutix Inc
Employees
274
CEO
Mr. Antony Mattessich
Industry
Health Technology

Discover More

FAQs